SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 03 2021
Historique:
received: 15 09 2020
accepted: 18 02 2021
entrez: 3 3 2021
pubmed: 4 3 2021
medline: 1 4 2021
Statut: epublish

Résumé

Although models have been developed for predicting severity of COVID-19 from the medical history of patients, simplified models with good accuracy could be more practical. In this study, we examined utility of simpler models for estimating risk of hospitalization of patients with COVID-19 and mortality of these patients based on demographic characteristics (sex, age, race, median household income based on zip code) and smoking status of 12,347 patients who tested positive at Mass General Brigham centers. The corresponding electronic records were queried (02/26-07/14/2020) to construct derivation and validation cohorts. The derivation cohort was used to fit generalized linear models for estimating risk of hospitalization within 30 days of COVID-19 diagnosis and mortality within approximately 3 months for the hospitalized patients. In the validation cohort, the model resulted in c-statistics of 0.77 [95% CI 0.73-0.80] for hospitalization, and 0.84 [95% CI 0.74-0.94] for mortality among hospitalized patients. Higher risk was associated with older age, male sex, Black ethnicity, lower socioeconomic status, and current/past smoking status. The models can be applied to predict the absolute risks of hospitalization and mortality, and could aid in individualizing the decision making when detailed medical history of patients is not readily available.

Identifiants

pubmed: 33654180
doi: 10.1038/s41598-021-84603-0
pii: 10.1038/s41598-021-84603-0
pmc: PMC7925678
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4945

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007575
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL135342
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL136852
Pays : United States
Organisme : U.S. Department of Health and Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
ID : 5K01HL135342
Organisme : American Heart Association (American Heart Association, Inc.)
ID : 17IGMV33860009

Commentaires et corrections

Type : UpdateOf

Références

N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
Circulation. 2020 Jul 7;142(1):4-6
pubmed: 32320270
J Infect. 2020 Aug;81(2):e93-e95
pubmed: 32417309
J Am Med Inform Assoc. 2018 Oct 1;25(10):1419-1428
pubmed: 29893864
NPJ Digit Med. 2019;2:
pubmed: 31119199
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
JAMA. 2015 Jan 6;313(1):29-30
pubmed: 25562260
Am J Infect Control. 2021 Feb;49(2):238-246
pubmed: 32659414
Health Aff (Millwood). 2020 Sep;39(9):1624-1632
pubmed: 32663045
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Clin Infect Dis. 2020 Jul 28;71(15):896-897
pubmed: 32271368
JAMA Pediatr. 2020 Oct 1;174(10):e202430
pubmed: 32492092
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
JAMA Intern Med. 2020 Jul 15;:
pubmed: 32667668
Obesity (Silver Spring). 2020 Jul;28(7):1200-1204
pubmed: 32352637
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
EClinicalMedicine. 2020 Jun 03;23:100404
pubmed: 32632416
Intern Emerg Med. 2020 Aug;15(5):853-856
pubmed: 32430652
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
Curr Probl Cardiol. 2020 Aug;45(8):100617
pubmed: 32402515
Eur J Intern Med. 2020 May;75:107-108
pubmed: 32192856
Med Care. 2014 Feb;52(2):144-8
pubmed: 24309669
Am J Cardiovasc Drugs. 2020 Aug;20(4):311-324
pubmed: 32578167

Auteurs

Hesam Dashti (H)

Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Elise C Roche (EC)

Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

David William Bates (DW)

Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Samia Mora (S)

Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. smora@bwh.harvard.edu.
Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. smora@bwh.harvard.edu.

Olga Demler (O)

Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH